Tuberculosis (TB) is among the biggest killers of people living with HIV (PLHIV) even in the era of increased access to anti-retroviral therapy (ART). TB incidence and recurrence rates, even if reduced by ART, remain high in PLHIV. The risk of developing active TB disease in PLHIV with latent infection increases up to 15% annually, in contrast to a life time risk of 10% among HIV negatives. PLHIV have significant increases in the incidence of smear-negative pulmonary and extra-pulmonary TB, which are difficult to diagnose and have inferior treatment outcomes, including excessive early mortality.
Extra-pulmonary TB is TB of any other part of body except lungs (TB in lungs is referred to as pulmonary TB). For public health reasons, governments want to find all cases of pulmonary TB as they are spreading TB through cough (infectious) – but cases of extra-pulmonary TB don't spread TB by coughing, and is not easy to transmit. Apparently pulmonary TB gains more public health priority from the governments. However, PLHIV are at an increased risk of developing extra-pulmonary TB - for instance, lymph node TB is common among PLHIV. To reduce TB related mortality in PLHIV, preventing, diagnosing and treating extra-pulmonary TB is as much a public health priority as pulmonary TB is.
According to the data of Revised National TB Control Programme (RNTCP) in India, out of the total new TB cases in first two quarters of 2008, 18% were of extra-pulmonary TB. Since 2004, cases of extra-pulmonary TB have increased by 3% in 2008, as per RNTCP data. Out of these extra-pulmonary TB, 30% were of pleural effusion, 10% abdominal TB, 8% bone TB, 47% lymph node TB, 2% TB meningitis and 3% TB elsewhere in body except lungs. More than 11,000 people had died due to extra-pulmonary TB (2005-07) in India alone.